Search research articles
Contact Us
Filters
Showing results (51-60 of 68) with videos related to
Page
of 7
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 4, 2006
166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy
Hazel B Breitz, Richard E Wendt, Michael S Stabin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2002
2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome
Alexander M Spence, Mark Muzi, Michael M Graham, et al.
Nuclear Medicine and Biology
|
October 9, 2007
Challenges in clinical studies with multiple imaging probes
Kenneth A Krohn, Finbarr O'Sullivan, John Crowley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2007
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma
Ajay K Gopal, Joseph G Rajendran, Ted A Gooley, et al.
Plos One
|
March 3, 2012
NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine
Seth M Pollack, Yonqing Li, Megan J Blaisdell, et al.
Molecular Imaging and Biology
|
October 17, 2018
Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)
Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.
Molecular Imaging and Biology
|
October 31, 2013
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)
Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.
Cancer
|
February 24, 2012
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma
Seth M Pollack, Achim A Jungbluth, Benjamin L Hoch, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc
|
January 18, 2002
Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET
William B Eubank, David A Mankoff, Hubert J Vesselle, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 21, 2014
Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease
Anand K Deo, Soo Borson, Jeanne M Link, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 68) with videos related to
Sort By:
Page
of 7
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 4, 2006
166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy
Hazel B Breitz, Richard E Wendt, Michael S Stabin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2002
2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome
Alexander M Spence, Mark Muzi, Michael M Graham, et al.
Nuclear Medicine and Biology
|
October 9, 2007
Challenges in clinical studies with multiple imaging probes
Kenneth A Krohn, Finbarr O'Sullivan, John Crowley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2007
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma
Ajay K Gopal, Joseph G Rajendran, Ted A Gooley, et al.
Plos One
|
March 3, 2012
NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine
Seth M Pollack, Yonqing Li, Megan J Blaisdell, et al.
Molecular Imaging and Biology
|
October 17, 2018
Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)
Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.
Molecular Imaging and Biology
|
October 31, 2013
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)
Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.
Cancer
|
February 24, 2012
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma
Seth M Pollack, Achim A Jungbluth, Benjamin L Hoch, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc
|
January 18, 2002
Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET
William B Eubank, David A Mankoff, Hubert J Vesselle, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 21, 2014
Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease
Anand K Deo, Soo Borson, Jeanne M Link, et al.
Page
of 7